Page 7 - Wockhardt

Wockhardt seeks G-20 aid for antibiotics

This may help contain the problem of anti-microbial drug resistance

Wockhardt Shendra plant yet to get Irish regulator's nod

Wockhardt which has received US FDA warning letters on four of its plants is now facing an issue with Ireland's drug regulator.The Irish drug regulator did not recommend the renewal of good manufacturing practices (GMP) certificate of Wockhardt's Shendra plant in Maharashtra and has advised the drug maker to to take corrective actions following an inspection. This is contrary to the claim made by Wockhardt in its notification to the stock exchange on Tuesday in which it said Irish regulator has recommended the renewal of the GMP certificate.The development comes within a week of US Food and Drugs Administration issuing a warning letter to Wockhardt's manufacturing unit in the US.In an emailed response Ireland's Health Products Regulatory Authority (HPRA) said an inspection was carried at Shendra for five days till March 3 covering some non sterile dosage forms. Injectable dosage forms were not within the scope of the inspection." The company (Wockhardt) was advised that corrective ..

Wockhardt falls over 5% as US unit gets FDA warning letter

The stock dipped nearly 7% to Rs 701 on the BSE in early morning trade

Another USFDA warning for Wockhardt; US plant faces product approval freeze

Three Indian plants already under alert; Non-compliance shaves off 66% in US revenue in last 4 years

Wockhardt gains as German regulator clears Ankaleshwar plant

The stock was up 6% to Rs 713 on the BSE in early morning trade

Wockhardt's Ankaleshwar facility gets clearance from German regulator

USFDA had issued warning to the company for violating good manufacturing practice norms

Wockhardt US business, stock under pressure over regulatory action

Share of US business revenue down to 17%

USFDA issues warning letter to Wockhardt's Ankleshwar plant

USFDA has already banned the import of products from the facility into the US market since August 5, 2016

USFDA warning to Wockhardt's Ankleshwar plant over data integrity issues

Three of firm's units under import alert; FDA cites failure to check microbiological contamination

Wockhardt shares jump 3% as Daman unit gets GMP certificate from UK MHRA

On BSE, the scrip opened at Rs 699 and jumped 3.24 per cent to an early high of Rs 704.

Wockhardt ED Huzaifa Khorakiwala to raise Rs 125cr for health fund

Executive Director of Wockhardt Ltd Huzaifa Khorakiwala has launched a healthcare angel fund

Wockhardt gains as Daman unit gets GMP certificate from UK MHRA

The stock hit an intra-day high of Rs 723, with a combined 1.6 million shares exchanging hands on the counter on the BSE and NSE

Wockhardt hits fresh 52-week low on warning letter to C P Pharma

The stock hit a fresh 52-week low of Rs 659, down 4.5% on BSE in early morning trade.

Nothing exciting about Wockhardt stock as yet

US sales continue to decline, pressuring profit and dampening the Street sentiment

Wockhardt hits 52-week low

The stock hit a 52-week low of Rs 683 in intra-day trade, down 16% in past seven trading sessions post Q2 results.

No critical observation by UK health regulator: Wockhardt

In December 2015, Wockhardt received a GMP certificate from the UK health regulator for its Chikalthana plant after an inspection

Wockhardt surges on heavy volumes

The stock urged 14% to Rs 959 on the NSE on back of heavy volumes.

Wockhardt shares down nearly 4% as Q1 net profit dives

Wockhardt on Saturday reported a fall of 82.65 per cent in consolidated net profit to Rs 15.89 crore for the first quarter ended June 30

Expanding markets, launching new products for growth: Wockhardt

Company has always believed that R&D is the key to the future, said Wockhardt Chairman and group CEO Habil Khorakiwala

Wockhardt Q1 net profit dives 80% to Rs 16 cr

The India business of the company grew a marginal 10 per cent, despite launching 11 new products in the market